ReviewTranslational neurodegeneration2026
Proximity labeling in neuroscience: decoding molecular landscapes for precision neurology.
Review in Translational neurodegeneration, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The intricate cellular architecture and dynamic molecular interplay in the nervous system have long challenged mechanistic studies of neurological diseases. Conventional approaches often miss the transient, low-affinity, or spatially confined interactions that underlie neural homeostasis and pathogenesis. Proximity labeling (PL) technologies overcome this limitation by enabling in situ capture of these elusive molecular events within living systems. Through spatially restricted biotinylation, PL methods, including engineered biotin ligases (e.g., TurboID), peroxidases (e.g., APEX2), and emerging photocatalytic platforms, allow high-resolution mapping of proteomes and interactomes within defined subcellular compartments, cell types, and cell-cell interfaces. In this review, we systematically outline the principles of PL and its transformative applications in constructing molecular atlases of the nervous system. We highlight how these tools are revolutionizing our understanding of brain function by elucidating pathophysiological mechanisms in Alzheimer's disease, Parkinson's disease and other neurological disorders. Furthermore, we discuss how PL accelerates the translation of basic research into clinical practice by facilitating the discovery of mechanistic biomarkers and druggable targets. Finally, we address current challenges and future directions, including integration with multi-omics and single-cell methodologies, and conclude that PL can advance precision neurology by bridging molecular neurobiology with therapeutic innovation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.